Corporate Update At the 2026 J.P. Morgan Healthcare Conference, Ionis Pharmaceuticals announced significant adjustments to its commercial expectations for its flagship product, Tryngolza (olezarsen). Following positive market feedback and robust clinical results, the company now aims for peak sales exceeding $2 billion.
Key Facts:
-
Forecast adjustment: The projected peak revenue for Tryngolza in treating severe hypertriglyceridemia (sHTG) has been raised from over $1 billion to more than $2 billion.
-
Scientific backing: This revision follows phase 3 trial data showing that Tryngolza reduced triglyceride levels by 55% to 72%. Notably, the risk of acute pancreatitis (AP)—a dangerous complication—dropped by 85% after one year of therapy.
-
Commercial timeline: Ionis submitted its application to the FDA last month, seeking priority review. Pending approval, a launch for the sHTG indication is anticipated in July of this year.
-
Market momentum: Tryngolza previously launched for familial chylomicronemia syndrome (FCS), generating $105 million in 2025. This success marks Ionis’s evolution from an R&D-focused organization into a fully commercial biopharma company.
-
Operational readiness: The company has already hired a field force of approximately 200 staff to manage the launch and address the millions of potential patients within the sHTG market.